Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Human Genetic Therapies Boosts Shire, Thanks To Replagal Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme's inability to provide Fabry disease patients with Fabrazyme has created an opening for Replagal, whose half-year sales are up 77 percent year-over-year.

You may also be interested in...



Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business

Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.

Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business

Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.

Shire Emphasizes The GI Space In Its Bid For Movetis

Only five years ago, Shire's specialty pharma business consisted of one product, Adderall XR, one market, the U.S., and one patient type - children. Multiple generics companies had filed ANDAs, however, and the company was looking to broaden its base

Related Content

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel